Scheduling, administration, biomarkers, and practical guidance.
Start at 0.25 mg for four weeks, then step up at 4-week intervals (0.5, 1.0, 1.7, 2.4 mg) as tolerated. Target maintenance typically 1.0–2.4 mg weekly. Slow titration is the primary tool to manage nausea and vomiting.
Step up by 2.5 mg every 4 weeks to a target maintenance dose (5, 7.5, 10, 12.5, or 15 mg). Titrate by GI tolerance rather than weight-loss rate.
Baseline Tier-2 dosing. Subcutaneous or intramuscular — oral bioavailability is unvalidated. Cycle rather than run continuously.
Extended protocol used in some clinical settings. Undertested relative to the standard 3× weekly cycle; reserve for monitored use.
Standard Russian clinical protocol. Oral — one of the few peptides in this class with documented oral bioavailability. Can be repeated 2× yearly. Non-responder rate ~50% — treat as a trial of one.
Used primarily for HIV-associated visceral fat. Cycle discipline needed to prevent GHRH receptor desensitisation. Glucose monitoring advised despite neutral trial data (mechanism-based caution).